2004-2006 / University of North Carolina Hospitals, Fellowship, Nephrology
2001-2004 / University of North Carolina Hospitals, Residency, Internal Medicine
1997-2001 / University of North Carolina, Chapel Hill, NC, Doctor of Medicine
1993-1997 / University of North Carolina, Chapel Hill, NC, Bachelor of Science, Chemistry
Work Experience
2013-Present / Research Director, Mountain Kidney and Hypertension Associates, PA
2006-Present / Clinical Nephrologist, Mountain Kidney and Hypertension Associates, PA
2004-2006 / Fellow in Nephrology, University of North Carolina Hospitals
2001-2004 / Medical Residency, Internal Medicine, University of North Carolina Hospitals
Credentials
Medical License / North Carolina Physician License - 200401147
Certification / North Carolina Medical Board - 104158
American Board of Internal Medicine, 2004, 2014
American Board of Nephrology, 2006, 2016
Hospital Affiliations
Mission-St. Joseph's Health System
CarePartners Rehabilitation Hospital
McDowell Hospital
Transylvania Regional Hospital
Highlands-Cashiers Regional Hospital
Angel Medical Center
Blue Ridge Regional Hospital
Haywood Regional Medical Center
Harris Regional Hospital
Professional Associations
American Society of Nephrology
Renal Physicians Association
Professional Affiliations / Committees
American Society of Nephrology
Renal Physicians Association
Honors and Awards
University of North Carolina School of Medicine, The Medical Alumni Scholarship
The Thomas Dark Scholarship
University of North Carolina at Chapel Hill
Morehead Scholar
Phi Beta Kappa
Research
Sub-Investigator
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Using GENZ-644470 and Sevelamer Carbonate in Hyperphosphatemic Chronic Kidney Disease Patients on Hemodialysis
Sub-Investigator
A Phase II, Randomized, Open-Label, Dose Titration, Efficacy and Safety Study of FGCL-4592 in Non-Dialysis Chronic Kidney Disease Patients with Anemia
Sub-Investigator
An Open-Label, Extension Study to Evaluate the Efficacy and Safety of FGCL-4592 for the Long-Term Maintenance Treatment of Anemia in Dialysis and Non-Dialysis Patients with Chronic Kidney Disease
Sub-Investigator
Bardoxolone Methyl in Patients with Chronic Kidney Disease and Type II Diabetes: the Occurrence of Renal Events (BEACON)
Principal Investigator
Burden of AV Graft and Fistula Complications in chronic kidney disease patients (GRAFIC)
Principal Investigator
RADAR: Reducing Residual Albuminuria in Subjects with Diabetes and Nephropathy with Atrasentan– A Phase 2B, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety and Efficacy
Sub-Investigator
A Randomized, Placebo-Controlled, Phase III Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents (CRUISE 1) Study
Sub-Investigator
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily Administration of a Phosphodiesterase 5 Inhibitor in Adults with Type 2 Diabetes and Overt Nephropathy
Sub-Investigator
An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 Compared with Sevelamer Carbonate Followed by a Randomised Comparison of PA21- Maintenance Dose Versus PA21- Low Dose in Dialysis Patients with Hyperphosphatemia
Sub-Investigator
An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre Phase 3 Study to Investigate the Long term Safety, Tolerability and Efficacy of PA21 Compared with Sevelamer Carbonate in Dialysis Patients with Hyperphosphataemia, Extension Study
Sub-Investigator
A Three Period, 58-Week Safety and Efficacy Trial of KRX-0502 in Patients with End Stage Renal Disease (ESRD) on Dialysis
Sub-Investigator
A Long-Term Safety Extension Trial of KRX-0502 (ferric citrate) in Patients with End-Stage Renal Disease (ESRD) on Dialysis
Sub-Investigator
A Phase 2 Study of KRX-0502 in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects with Stage III to V Chronic Kidney Disease Not on Dialysis
Principal Investigator
A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia
Sub-Investigator
A Four Week, Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of GSK1278863 in Subjects with Anemia Associated with Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Sub-Investigator
A Four-Week, Phase IIa, Randomized, Active-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Switching Subjects From a Stable Dose of Recombinant Human Erythropoietin to GSK1278863 in Hemodialysis-Dependent Subjects with Anemia Associated with Chronic Kidney Disease
Principal Investigator
Phase 2B Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 In Subject With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3A-G5 (Stages 3, 4, and 5) (Pre-Dialysis)
Principal Investigator
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily Administration of a Chemokine CCR2/5 Receptor Antagonist (PF-04634817) in Adults with Type 2 Diabetes and Overt Nephropathy
Principal Investigator
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects with Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency
Principal Investigator
A Long-term Safety and Efficacy Study of CTAP101 Capsules in Subjects with Stages 3 or 4 Chronic Kidney Disease, Secondary Hyperparathyroidism and Vitamin Insufficiency (Extension of Study CTAP101-CL-3001 or CTAP101-CL-3002)
Sub-Investigator
A Phase 2a, Placebo-Controlled, Randomized, Single-Blind Study of Weekly Doses of GCS-100 in Patients with Chronic Kidney Disease
Sub-Investigator
A Phase 2 Extension Study of Study GCS-100-CS-4002
Principal Investigator
Study Protocol for the Validation of the Nausea/Vomiting Symptom Assessment (NVSA) Patient Reported Outcome Instrument Among Chronic Kidney Disease Patients on Dialysis With Secondary Hyperparathyroidism
Sub-Investigator
A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia in Adult Subjects with Non-Dialysis Dependent Chronic Kidney Disease
Sub-Investigator
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy (CREDENCE)
Sub-Investigator
A Phase 2 Dose-ranging, Double-blind, Placebo-controlled Study Evaluating the Efficacy, Safety and Tolerability of GS-4997 on Subjects with Stage 3 or Stage 4 Diabetic Kidney Disease
Sub-Investigator
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group, Phase 2, Two-Part Adaptive Study to Evaluate the Safety and Efficacy of VPI 2690B Injection in Patients with Nephropathy Due to Diabetes
Principal Investigator
A Phase 2b, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of GCS-100 in Patients with Chronic Kidney Disease Caused by Diabetes
Sub-Investigator
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients
Principal Investigator
A Phase 3b, Multi-center, Randomized-withdrawal, Placebo-controlled, Double-blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45 to 120 mg/day, Split-dose) in Subjects with Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease
Sub-Investigator
A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy - SONAR: Study of Diabetic Nephropathy with Atrasentan
Principal Investigator
Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT - CORRECTION)
Principal Investigator
Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT - CONVERSION)
Sub-Investigator
A Phase III, Randomized, Multicenter, Double-Blind, Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)
Principal Investigator
A Phase 3b, Multi-center, Open-label trial to Evaluate the Long-Term Safety of Immediate-release Tolvaptan in Subjects with Autosomal Dominant Polycystic Kidney Disease
Principal Investigator
A Phase 4, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lesinurad 200mg in Combination with a Xanthine Oxidase Inhibitor (XOI), Compared with an XOI alone, in Subjects with Gout and Estimated Creatinine Clearance 30-<60 mL/min Who Have Not Achieved Target Serum Uric Acid Levels on an XOI Alone
Sub-Investigator
A Phase 3, Randomized, Open-label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects with Dialysis-Dependent Chronic Kidney Disease (DD-CKD) (INNO2VATE – CONVERSION)
Principal Investigator
A phase III, randomized, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer) and iron sucrose in subjects with iron deficiency anemia and non-dialysis-dependent chronic kidney disease
Sub-Investigator
A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (DAPA-CKD)
Principal Investigator
A Phase 2, randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy, safety, and pharmacokinetics of KBP-5074 in patients with moderate-to-severe chronic kidney disease and uncontrolled hypertension
Sub-Investigator
A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd)
Sub-Investigator
A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease (FALCON)
Sub-Investigator
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate REduction in Inflammation in PatientS with advanced Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition (RESCUE)
Sub-Investigator
A Two-Part Proof-of-Concept Phase 2 Study: An Open-Label Dose-Ranging Phase (Part A) Followed by a Randomized, Single-Blind, Placebo-Controlled Phase (Part B) Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia (ReduKx)
Sub-Investigator
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SNF472 When Added to Background Care for the Treatment of Calciphylaxis
Principal Investigator
A Phase 2, Open-Label, Basket Study of Atrasentan in Patients with Proteinuric Glomerular Diseases (AFFINITY)
Principal Investigator
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (ALIGN)
Principal Investigator
A Phase 2b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients with Chronic Kidney Disease with Estimated Glomerular Filtration Rate (eGFR) Between 20 and 60 mL/min/1.73 m2 (ZENITH)
